The six most frequent targets in GIST clinical trials were KIT, PDGFRA, KDR (VEGFR2), FLT3, FLT1 (VEGFR1), and FLT4/VEGFR3 in that order. The gene discussed is FLT3; the disease is gastrointestinal stromal tumor.